Table 3. The cost of treatment coverage with sofosbuvir or ledipasvir/sofosbuvir of different proportions of patients with viraemic HCV infection (for point estimates and uncertainty intervals) as a proportion of PPP-adjusted current total pharmaceutical expenditure.
| Country | Proportion of TPE (UI) | |||||||
|---|---|---|---|---|---|---|---|---|
| Sofosbuvir Treatment Coverage | Ledipasvir/Sofosbuvir Treatment Coverage | |||||||
| 10% | 50% | 75% | 100% | 10% | 50% | 75% | 100% | |
| Poland | 16.2% (11.1%, 40.6%) | 81.1% (55.4%, 203.0%) | 121.6% (83.1%, 304.5%) | 162.2% (110.9%, 405.9%) | 19.1% (13.0%, 45.1%) | 95.3% (65.1%, 225.5%) | 142.9% (97.7%, 338.3%) | 190.5% (130.3%, 451.0%) |
| New Zealand | 15.5% (8.9%, 26.8%) | 77.5% (44.5%, 133.8%) | 116.3% (66.8%, 200.6%) | 155.0% (89.0%, 267.5%) | 15.1% (9.3%, 26.1%) | 75.6% (46.4%, 130.4%) | 113.4% (69.7%, 195.6%) | 151.2% (92.9%, 260.8%) |
| Portugal | 13.3% (8.7%, 23.0%) | 66.6% (43.6%, 114.9%) | 99.9% (65.3%, 172.3%) | 133.2% (87.1%, 229.8%) | 16.5% (9.9%, 28.5%) | 82.6% (49.4%, 142.6%) | 124.0% (74.2%, 213.9%) | 165.3% (98.9%, 285.2%) |
| Italy | 11.1% (7.5%, 21.4%) | 55.6% (37.4%, 107.1%) | 83.4% (56.1%, 160.7%) | 111.1% (74.8%, 214.3%) | 12.3% (8.5%, 25.2%) | 61.7% (42.5%, 125.9%) | 92.6% (63.7%, 188.8%) | 123.5% (84.9%, 251.8%) |
| Spain | 10.0% (5.4%, 16.7%) | 50.0% (27.1%, 83.3%) | 75.0% (40.7%, 125.0%) | 100.0% (54.3%, 166.7%) | 11.2% (5.4%, 17.0%) | 56.0% (26.9%, 85.2%) | 83.9% (40.3%, 127.9%) | 111.9% (53.7%, 170.5%) |
| Greece | 9.7% (4.8%, 15.2%) | 48.3% (23.9%, 76.2%) | 72.4% (35.8%, 114.3%) | 96.6% (47.7%, 152.4%) | Not available | |||
| Slovakia | 7.0% (4.4%, 9.9%) | 35.2% (22.0%, 49.5%) | 52.8% (33.0%, 74.3%) | 70.4% (44.0%, 99.0%) | Not available | |||
| Japan | 5.2% (2.9%, 9.5%) | 26.1% (14.6%, 47.7%) | 39.1% (21.9%, 71.6%) | 52.1% (29.2%, 95.5%) | 6.8% (3.9%, 11.1%) | 33.8% (19.5%, 55.5%) | 50.7% (29.3%, 83.2%) | 67.6% (39.0%, 110.9%) |
| Switzerland | 5.2% (2.9%, 9.0%) | 26.0% (14.3%, 44.8%) | 39.0% (21.5%, 67.2%) | 52.0% (28.6%, 89.6%) | 5.6% (2.6%, 6.7%) | 28.1% (12.9%, 33.7%) | 42.2% (19.4%, 50.6%) | 56.3% (25.8%, 67.5%) |
| United States | 5.2% (2.6%, 8.8%) | 25.9% (13.2%, 43.9%) | 38.8% (19.8%, 65.9%) | 51.7% (26.4%, 87.9%) | 5.8% (2.9%, 9.7%) | 29.1% (14.7%, 48.6%) | 43.6% (22.1%, 72.8%) | 58.2% (29.4%, 97.1%) |
| Luxembourg | 5.1% (2.6%, 7.9%) | 25.5% (13.1%, 39.5%) | 38.2% (19.6%, 59.3%) | 50.9% (26.1%, 79.1%) | 6.4% (3.6%, 10.7%) | 32.1% (18.1%, 53.7%) | 48.2% (27.1%, 80.6%) | 64.3% (36.1%, 107.4%) |
| Ireland | 4.2% (2.5%, 6.2%) | 21.2% (12.7%, 31.1%) | 31.8% (19.1%, 46.6%) | 42.4% (25.4%, 62.2%) | Not available | |||
| Denmark | 3.9% (2.3%, 6.1%) | 19.6% (11.5%, 30.3%) | 29.4% (17.3%, 45.4%) | 39.2% (23.1%, 60.6%) | 5.9% (3.2%, 10.3%) | 29.3% (15.8%, 51.3%) | 43.9% (23.7%, 76.9%) | 58.6% (31.6%, 102.6%) |
| Belgium | 3.1% (1.9%, 5.0%) | 15.6% (9.6%, 24.9%) | 23.5% (14.3%, 37.3%) | 31.3% (19.1%, 49.8%) | Not available | |||
| Norway | 3.0% (1.8%, 4.1%) | 15.2% (8.8%, 20.6%) | 22.8% (13.3%, 30.9%) | 30.4% (17.7%, 41.2%) | 3.4% (2.3%, 5.8%) | 16.9% (11.3%, 29.1%) | 25.4% (16.9%, 43.7%) | 33.8% (22.5%, 58.3%) |
| Canada | 3.0% (1.8%, 3.9%) | 14.9% (8.8%, 19.6%) | 22.4% (13.2%, 29.4%) | 29.9% (17.6%, 39.2%) | 3.6% (2.3%, 5.9%) | 18.2% (11.4%, 29.3%) | 27.3% (17.1%, 43.9%) | 36.4% (22.8%, 58.6%) |
| United Kingdom | 3.0% (1.6%, 3.8%) | 14.9% (8.1%, 19.2%) | 22.3% (12.2%, 28.8%) | 29.7% (16.2%, 38.3%) | 3.3% (2.0%, 4.3%) | 16.6% (9.9%, 21.3%) | 24.8% (14.8%, 32.0%) | 33.1% (19.7%, 42.7%) |
| Finland | 2.9% (1.6%, 3.5%) | 14.4% (8.1%, 17.7%) | 21.6% (12.2%, 26.6%) | 28.8% (16.2%, 35.5%) | 3.4% (2.0%, 4.3%) | 16.9% (9.9%, 21.6%) | 25.3% (14.8%, 32.4%) | 33.8% (19.8%, 43.2%) |
| Sweden | 2.7% (1.4%, 3.4%) | 13.5% (6.9%, 17.1%) | 20.3% (10.4%, 25.6%) | 27.0% (13.8%, 34.2%) | 3.2% (1.9%, 4.2%) | 15.9% (9.5%, 21.2%) | 23.9% (14.2%, 31.9%) | 31.9% (19.0%, 42.5%) |
| Austria | 2.1% (1.1%, 3.4%) | 10.7% (5.7%, 17.0%) | 16.1% (8.5%, 25.5%) | 21.4% (11.4%, 34.1%) | 2.4% (1.4%, 3.3%) | 12.0% (7.1%, 16.5%) | 18.0% (10.6%, 24.7%) | 24.0% (14.2%, 32.9%) |
| Germany | 2.1% (0.6%, 2.9%) | 10.5% (2.9%, 14.7%) | 15.8% (4.4%, 22.0%) | 21.1% (5.9%, 29.4%) | 2.6% (1.5%, 3.8%) | 13.1% (7.7%, 19.2%) | 19.7% (11.6%, 28.8%) | 26.3% (15.5%, 38.3%) |
| France | 1.8% (0.4%, 2.8%) | 9.0% (2.0%, 13.9%) | 13.4% (3.1%, 20.8%) | 17.9% (4.1%, 27.7%) | 2.0% (0.8%, 3.3%) | 10.0% (3.9%, 16.3%) | 15.1% (5.9%, 24.5%) | 20.1% (7.9%, 32.6%) |
| Netherlands | 1.0% (0.4%, 1.8%) | 5.2% (2.0%, 9.0%) | 7.9% (3.0%, 13.6%) | 10.5% (4.0%, 18.1%) | 1.4% (0.4%, 2.4%) | 7.0% (2.2%, 12.1%) | 10.5% (3.3%, 18.1%) | 14.0% (4.4%, 24.2%) |